TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 29150482

Group type: EXPERIMENTAL
Intervention: Mammography screening (invited group)
Number of subjects: 77080

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 77080
Study: 26442791

Group type: EXPERIMENTAL
Intervention: Numbers + icon arrays
Number of subjects: 276

Group type: EXPERIMENTAL
Intervention: Numbers + experienced format
Number of subjects: 276

Group type: COMPARATOR
Intervention: Numbers + icon array format
Number of subjects: 276
Study: 25099689

Group type: EXPERIMENTAL
Intervention: TETRA handset exposure at 6 W/kg
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: TETRA handset exposure at 1.5 W/kg
Number of subjects: 15

Group type: COMPARATOR
Intervention: Sham exposure
Number of subjects: 15
Study: 22232018

Group type: EXPERIMENTAL
Intervention: Triple P (group-based universal parent training program)
Number of subjects: 1675

Group type: COMPARATOR
Intervention: Control condition (no intervention)
Number of subjects: 1675
Study: 19387822

Group type: EXPERIMENTAL
Intervention: Multi-level participatory intervention to increase influenza vaccination
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Multi-level participatory intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control building (no specific intervention mentioned)
Number of subjects: 0
Study: 18247252

Group type: EXPERIMENTAL
Intervention: Linear exercise testing protocol
Number of subjects: 28

Group type: COMPARATOR
Intervention: Stepwise exercise testing protocol
Number of subjects: 28
Study: 15072254

Group type: COMPARATOR
Intervention: Hydroxyethyl starch (HES) in volume ratios of 2:1 (Group II)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Hydroxyethyl starch (HES) in volume ratios of 1:2 (Group IV)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Hydroxyethyl starch (HES) in volume ratios of 0:1 (Group V)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Hydroxyethyl starch (HES) in volume ratios of 1:0 (Group I)
Number of subjects: 50
Study: 12002198

Group type: EXPERIMENTAL
Intervention: Photodynamic therapy with verteporfin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Laser photocoagulation
Number of subjects: 0
Study: 9825502

Group type: EXPERIMENTAL
Intervention: Antibodies to bacterial antigens (Reglicolipid, Streptococcus agalactiae polysaccharide, Staphylococcus aureus teichoic acid)
Number of subjects: 2
Study: 7797824

Group type: EXPERIMENTAL
Intervention: pantoprazole (40 mg once daily)
Number of subjects: 249

Group type: COMPARATOR
Intervention: ranitidine (150 mg b.i.d.)
Number of subjects: 249

Group type: EXPERIMENTAL
Intervention: pantoprazole
Number of subjects: 249

Group type: COMPARATOR
Intervention: ranitidine
Number of subjects: 249
Study: 2121268

Group type: EXPERIMENTAL
Intervention: 20 g alcohol in concentrations of 75, 180 and 300 ml/l water; RMR measured for 60 min; thermic effect measured for 90 min.
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: 20 g alcohol in a 180 ml/l solution plus a meal of food (2 MJ); DIT measured for 240 min.
Number of subjects: 22

Group type: COMPARATOR
Intervention: Isoenergetic meal of food alone (2.55 MJ) plus a placebo aperitif containing no alcohol; DIT measured for 240 min.
Number of subjects: 22
Study: 385764

Group type: EXPERIMENTAL
Intervention: RIT 4025 live recombinant strain (10(7.2) EID 50/dose, one or two doses at 2 weeks' interval)
Number of subjects: 253

Group type: EXPERIMENTAL
Intervention: Inactivated vaccine (360 i.u. A/Port Chalmers/1/73 (H3N2), 300 i.u. A/Scotland/840/74 (H3N2), 300 i.u. B/Hong Kong/8/73, 300 i.u./dose, one injection)
Number of subjects: 253

Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 253
Study: 30561704

Group type: EXPERIMENTAL
Intervention: Intravenous acetaminophen (1 g every eight hours, three doses)
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Oral acetaminophen (1 g every eight hours, three doses)
Number of subjects: 141

Group type: COMPARATOR
Intervention: No acetaminophen
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Intravenous acetaminophen
Number of subjects: 141
Study: 28509573

Group type: EXPERIMENTAL
Intervention: Atomoxetine (ATX)
Number of subjects: 128

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Atomoxetine + Parent Training (PT)
Number of subjects: 128

Group type: COMPARATOR
Intervention: Placebo + Parent Training (PT)
Number of subjects: 128
Study: 26066761

Group type: EXPERIMENTAL
Intervention: Curcuma extract with visible light phototherapy (VLRT)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Simulated visible light phototherapy (VLST)
Number of subjects: 21
Study: 23901394

Group type: EXPERIMENTAL
Intervention: Frozen neck wrap targeting the carotid arteries at the neck
Number of subjects: 55

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 55
Study: 21606394

Group type: EXPERIMENTAL
Intervention: Carotid artery stenting
Number of subjects: 2502

Group type: COMPARATOR
Intervention: Carotid endarterectomy
Number of subjects: 2502

Group type: EXPERIMENTAL
Intervention: MI
Number of subjects: 2502

Group type: EXPERIMENTAL
Intervention: biomarker+ only
Number of subjects: 2502
Study: 20139856

Group type: EXPERIMENTAL
Intervention: IFX/AZA (Azathioprine 2-2.5 mg/kg/day)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: IFX/HC (Hydrocortisone 250 mg intravenously)
Number of subjects: 46
Study: 16914835

Group type: EXPERIMENTAL
Intervention: ADAS‐Cog
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: MMSE
Number of subjects: 15
Study: 15540740

Group type: EXPERIMENTAL
Intervention: Bicalutamide 150 mg/day
Number of subjects: 8113

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8113
Study: 11422108

Group type: EXPERIMENTAL
Intervention: Transdermal testosterone gel 100 mg/day
Number of subjects: 227

Group type: EXPERIMENTAL
Intervention: Transdermal testosterone gel 50 mg/day
Number of subjects: 227

Group type: COMPARATOR
Intervention: Transdermal testosterone patches (5 mg T/day)
Number of subjects: 227
Study: 9231954

Group type: EXPERIMENTAL
Intervention: Weekly phone calls to uncover problems and encourage use
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Written information about sleep apnea and importance of regular CPAP use
Number of subjects: 33

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 33
Study: 8193888

Group type: EXPERIMENTAL
Intervention: Spiral-acquisition computed tomography (SACT)
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Spiral-acquisition computed tomography (SACT) with pitch greater than 1.0
Number of subjects: 104

Group type: COMPARATOR
Intervention: Conventional computed tomography (CCT)
Number of subjects: 104
Study: 2902681

Group type: EXPERIMENTAL
Intervention: 150 mg zaltidine once daily for 4 weeks
Number of subjects: 135

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 135
Study: 31742670

Group type: EXPERIMENTAL
Intervention: Patient navigation
Number of subjects: 344

Group type: EXPERIMENTAL
Intervention: Patient navigation plus standard CDC print materials
Number of subjects: 344

Group type: EXPERIMENTAL
Intervention: Patient navigation plus culturally targeted print materials
Number of subjects: 344

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 344
Study: 30615248

Group type: EXPERIMENTAL
Intervention: Aerobic interval training in hypoxia (AitH; FiO2 = 17.2%; n = 13)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Sprint interval training in hypoxia (SitH; FiO2 = 17.2%; n = 15)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Aerobic interval training in normoxia (AitN; n = 15)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Sprint interval training in normoxia (SitN; n = 18)
Number of subjects: 59
Study: 28645949

Group type: EXPERIMENTAL
Intervention: 4.5 g/day S. maxima intake
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Physical systematic exercise programme at moderate intensity
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: S. maxima plus exercise
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 80
Study: 25253549

Group type: EXPERIMENTAL
Intervention: Real needle acupuncture on Zhubin (KI9)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo needle acupuncture
Number of subjects: 20
Study: 23769724

Group type: EXPERIMENTAL
Intervention: Low self-esteem group
Number of subjects: 30

Group type: COMPARATOR
Intervention: High self-esteem group
Number of subjects: 30
Study: 21445287

Group type: EXPERIMENTAL
Intervention: Se-enriched onion (50 µg/day)
Number of subjects: 119

Group type: COMPARATOR
Intervention: 200 µg/day Se-enriched yeast
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Influenza vaccine challenge
Number of subjects: 119
Study: 19419670

Group type: EXPERIMENTAL
Intervention: semi‐solid product
Number of subjects: 32

Group type: COMPARATOR
Intervention: liquid product
Number of subjects: 32
Study: 16414208

Group type: EXPERIMENTAL
Intervention: 68 Gy
Number of subjects: 641

Group type: COMPARATOR
Intervention: 78 Gy
Number of subjects: 641
Study: 15276686

Group type: EXPERIMENTAL
Intervention: Average nicotine (AN) cigarettes
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Low nicotine (LN) cigarettes
Number of subjects: 21
Study: 11509081

Group type: EXPERIMENTAL
Intervention: Entacapone (200 mg with each of 2-10 daily levodopa doses)
Number of subjects: 326

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 326

Group type: EXPERIMENTAL
Intervention: Entacapone
Number of subjects: 326

Group type: EXPERIMENTAL
Intervention: Entacapone withdrawal
Number of subjects: 326
Study: 9243565

Group type: EXPERIMENTAL
Intervention: Individual interview in the workplace
Number of subjects: 1200

Group type: EXPERIMENTAL
Intervention: Group-administered questionnaire in the workplace
Number of subjects: 1200

Group type: EXPERIMENTAL
Intervention: Telephone interview
Number of subjects: 1200

Group type: EXPERIMENTAL
Intervention: Individual interview off the worksite
Number of subjects: 1200

Group type: COMPARATOR
Intervention: Urinalysis
Number of subjects: 1200

Group type: COMPARATOR
Intervention: Hair analysis
Number of subjects: 1200
Study: 8480685

Group type: EXPERIMENTAL
Intervention: Zinc supplementation (10 mg Zn/d, n = 65)
Number of subjects: 130

Group type: COMPARATOR
Intervention: Placebo (n = 65)
Number of subjects: 130
Study: 3527691

Group type: EXPERIMENTAL
Intervention: Coping skills intervention
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Anxiety reduction intervention
Number of subjects: 33

Group type: COMPARATOR
Intervention: Information group (control)
Number of subjects: 33
Study: 31686577

Group type: EXPERIMENTAL
Intervention: Action observation training (AOT)
Number of subjects: 87

Group type: COMPARATOR
Intervention: Control training (C)
Number of subjects: 87
Study: 31745964

Group type: EXPERIMENTAL
Intervention: Peer-Assisted Learning (PAL)
Number of subjects: 40
Study: 30097067

Group type: EXPERIMENTAL
Intervention: Citrulline malate (CM) 8 g (1.11:1 ratio)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Citrulline malate (CM)
Number of subjects: 0
Study: 26834211

Group type: EXPERIMENTAL
Intervention: Secukinumab IV loading 10 mg/kg at baseline, Weeks 2 and 4, then SC 150 mg every 4 weeks (n = 88)
Number of subjects: 221

Group type: EXPERIMENTAL
Intervention: Secukinumab SC loading 150 mg once weekly for 5 weeks, then every 4 weeks (n = 89)
Number of subjects: 221

Group type: COMPARATOR
Intervention: Placebo (n = 44)
Number of subjects: 221

Group type: EXPERIMENTAL
Intervention: Pooled secukinumab
Number of subjects: 221

Group type: COMPARATOR
Intervention: Secukinumab and placebo
Number of subjects: 221
Study: 24145221

Group type: EXPERIMENTAL
Intervention: Ziprasidone augmentation of clozapine
Number of subjects: 40
Study: 22176998

Group type: EXPERIMENTAL
Intervention: Optimization of medical treatment with β-blockers and angiotensin-converting enzyme inhibitors
Number of subjects: 503

Group type: COMPARATOR
Intervention: No optimization of medical treatment (baseline 'SCD-HeFT criteria' not met)
Number of subjects: 503

Group type: COMPARATOR
Intervention: Group A1 (patients who maintained 'SCD-HeFT criteria')
Number of subjects: 503

Group type: COMPARATOR
Intervention: Group A2 (patients who improved)
Number of subjects: 503

Group type: COMPARATOR
Intervention: Group B1 (patients who developed 'SCD-HeFT criteria')
Number of subjects: 503

Group type: COMPARATOR
Intervention: Group B2 (patients who remained without 'SCD-HeFT criteria')
Number of subjects: 503
Study: 21519359

Group type: EXPERIMENTAL
Intervention: Intranasal calcitonin (200 IU daily)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study: 18318568

Group type: EXPERIMENTAL
Intervention: Zoledronic acid 4 mg administered as a 15-minute infusion every 3-4 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Zoledronic acid
Number of subjects: 0

Group type: COMPARATOR
Intervention: Zoledronic acid therapy
Number of subjects: 0
Study: 16278367

Group type: EXPERIMENTAL
Intervention: Sildenafil (50 mg)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Testosterone replacement therapy
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Sildenafil plus testosterone
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 12709719

Group type: COMPARATOR
Intervention: Moxifloxacin 800 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Levofloxacin 1000 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ciprofloxacin 1500 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Placebo
Number of subjects: 0
Study: 10898688

Group type: EXPERIMENTAL
Intervention: Intravenous magnesium sulfate (MgSO4) at doses of 1, 2, and 3 g
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Intravenous magnesium sulfate (MgSO4)
Number of subjects: 12
Study: 8799404

Group type: EXPERIMENTAL
Intervention: Peripheral dextrose (10 kcal/kg/day) for seven days following hepatectomy
Number of subjects: 19

Group type: COMPARATOR
Intervention: Hypertonic glucose
Number of subjects: 19
Study: 1811970

Group type: EXPERIMENTAL
Intervention: Functional appliance only
Number of subjects: 34

Group type: COMPARATOR
Intervention: Intermaxillary wiring with subsequent functional therapy and/or functional appliances
Number of subjects: 34
Study: 6347747

Group type: EXPERIMENTAL
Intervention: 15 mg of quazepam
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 30950694

Group type: EXPERIMENTAL
Intervention: Attentional shifting task with varying demands (low, medium, high load)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Attentional shifting task with high attentional load
Number of subjects: 50

Group type: COMPARATOR
Intervention: Attentional shifting task (nonshifting trials)
Number of subjects: 50
Study: 27077996

Group type: EXPERIMENTAL
Intervention: Protocol introduction with education and 3-month interim review
Number of subjects: 264

Group type: COMPARATOR
Intervention: Protocol introduction alone
Number of subjects: 264

Group type: EXPERIMENTAL
Intervention: Protocol introduction with education
Number of subjects: 264
Study: 25332355

Group type: EXPERIMENTAL
Intervention: Four reminders
Number of subjects: 283

Group type: EXPERIMENTAL
Intervention: ¥5.0 credit reward for replying
Number of subjects: 283

Group type: EXPERIMENTAL
Intervention: Feedback text message
Number of subjects: 283

Group type: COMPARATOR
Intervention: Control group (group 2)
Number of subjects: 283
Study: 24727262

Group type: EXPERIMENTAL
Intervention: Trabeculectomy
Number of subjects: 607

Group type: COMPARATOR
Intervention: Topical medications
Number of subjects: 607

Group type: EXPERIMENTAL
Intervention: Better intraocular pressure (IOP) control
Number of subjects: 607

Group type: EXPERIMENTAL
Intervention: Female sex
Number of subjects: 607

Group type: EXPERIMENTAL
Intervention: Visits 1 year prior to cataract extraction
Number of subjects: 607

Group type: EXPERIMENTAL
Intervention: Interaction between treatment and baseline MD
Number of subjects: 607
Study: 23043563

Group type: EXPERIMENTAL
Intervention: PSA-based screening with a threshold of ≥ 3.0 ng/mL
Number of subjects: 42376

Group type: EXPERIMENTAL
Intervention: PSA-based screening
Number of subjects: 42376

Group type: EXPERIMENTAL
Intervention: Repeat biopsies
Number of subjects: 42376
Study: 19543123

Group type: EXPERIMENTAL
Intervention: Medicare Advantage (MA)
Number of subjects: 390756

Group type: COMPARATOR
Intervention: Traditional fee-for-service (FFS) Medicare
Number of subjects: 390756

Group type: EXPERIMENTAL
Intervention: Preventive services in MA
Number of subjects: 390756

Group type: COMPARATOR
Intervention: Preventive services in FFS
Number of subjects: 390756

Group type: EXPERIMENTAL
Intervention: Office wait time and immunization rates in MA
Number of subjects: 390756
Study: 17518105

Group type: EXPERIMENTAL
Intervention: Form priming with related primes and targets (e.g., lou3 'hug'‐‐lou2 'hall')
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Form priming with unrelated primes and targets (e.g., lou3 'hug'‐‐jian4zhu0 'building')
Number of subjects: 0
Study: 15065478

Group type: EXPERIMENTAL
Intervention: Increase group (maintained EMG activity above 10 microV)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Decrease group (maintained EMG activity below 2 microV)
Number of subjects: 14
Study: 11785593

Group type: EXPERIMENTAL
Intervention: Alfentanil (0.5 mg IV)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Morphine (5 mg IV)
Number of subjects: 40
Study: 9737475

Group type: EXPERIMENTAL
Intervention: Low-molecular-weight heparins (LMWHs)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard heparin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 7921469

Group type: EXPERIMENTAL
Intervention: Female gender
Number of subjects: 5662

Group type: EXPERIMENTAL
Intervention: PC20FEV1 < or = 5 mg/ml (AHR5)
Number of subjects: 5662

Group type: EXPERIMENTAL
Intervention: PC20FEV1 < or = 25 mg/ml (AHR25)
Number of subjects: 5662
Study: 3268274

Group type: EXPERIMENTAL
Intervention: Reference group instructions (age group peers)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Reference group instructions (adults in general)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Reference group instructions (themselves at a younger age)
Number of subjects: 0

Group type: COMPARATOR
Intervention: No instructions (standard instructional format)
Number of subjects: 0
Study: 31034347

Group type: EXPERIMENTAL
Intervention: Conventional resin composite (PA: Peak Universal+Amelogen Plus, Ultradent)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Low-shrinkage flowable and nanoparticulate resin composites (ABF: Adper Single Bond 2+Filtek Bulk Fill Flow+Filtek Z350XT, 3M ESPE)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Low-shrinkage flowable and microhybrid resin composites (XST: XP Bond+SDR+TPH3, Dentsply)
Number of subjects: 53
Study: 30476361

Group type: EXPERIMENTAL
Intervention: Samidorphan (10 mg)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Samidorphan (30 mg)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Oxycodone (40 mg)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Pentazocine (30 mg)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Naltrexone (100 mg)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study: 28117843

Group type: EXPERIMENTAL
Intervention: Lithium (serum level 0.6 mmol l-1, n=20)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Quetiapine (flexibly dosed up to 800 mg per day, n=19)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Healthy controls (n=20)
Number of subjects: 26
Study: 26467791

Group type: EXPERIMENTAL
Intervention: Xylitol chewing gum
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Xylitol dissolvable chewable tablets
Number of subjects: 41

Group type: COMPARATOR
Intervention: Control group (no xylitol)
Number of subjects: 41
Study: 23230135

Group type: EXPERIMENTAL
Intervention: AIB1 in systemically untreated women
Number of subjects: 490

Group type: COMPARATOR
Intervention: Tamoxifen treatment in pre- and postmenopausal women
Number of subjects: 490

Group type: EXPERIMENTAL
Intervention: PAX2 in ER-positive patients receiving tamoxifen
Number of subjects: 490
Study: 21630176

Group type: EXPERIMENTAL
Intervention: Pre-operative home exercise sensorimotor training programme
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group (no therapy)
Number of subjects: 80
Study: 18054209

Group type: EXPERIMENTAL
Intervention: Paroxetine plus pindolol (2.5 mg t.i.d.)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Paroxetine plus placebo
Number of subjects: 50
Study: 17006066

Group type: EXPERIMENTAL
Intervention: Mechanical ventilation with lower tidal volumes (6 ml/kg) and 10 cm H2O PEEP
Number of subjects: 40

Group type: COMPARATOR
Intervention: Mechanical ventilation with higher tidal volumes (12 ml/kg) and no PEEP
Number of subjects: 40
Study: 14621239

Group type: EXPERIMENTAL
Intervention: Carbamide peroxide (11%, 13%, 16%, 21%)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Carbamide peroxide (16%, 21%)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Control solutions (tap water, Carbopol, Carbopol-urea)
Number of subjects: 180
Study: 10811092

Group type: EXPERIMENTAL
Intervention: cyclosporin A ophthalmic emulsion 0.05%
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: cyclosporin A ophthalmic emulsion 0.1%
Number of subjects: 162

Group type: COMPARATOR
Intervention: vehicle
Number of subjects: 162
Study: 8644961

Group type: EXPERIMENTAL
Intervention: No hyperbaric oxygen therapy (HBO)
Number of subjects: 4
Study: 1397669

Group type: EXPERIMENTAL
Intervention: Typhoid Vi CPS vaccine
Number of subjects: 637

Group type: COMPARATOR
Intervention: Heat‐killed whole‐cell typhoid vaccine
Number of subjects: 637
Study: 3932051

Group type: EXPERIMENTAL
Intervention: Misoprostol 50 micrograms, q.i.d.
Number of subjects: 703

Group type: EXPERIMENTAL
Intervention: Misoprostol 200 micrograms, q.i.d.
Number of subjects: 703

Group type: COMPARATOR
Intervention: Cimetidine 300 mg, q.i.d.
Number of subjects: 703
Study: 30712740

Group type: EXPERIMENTAL
Intervention: Yoga training for 8 weeks
Number of subjects: 64

Group type: COMPARATOR
Intervention: Control group (passive control)
Number of subjects: 64
Study: 28287800

Group type: EXPERIMENTAL
Intervention: Brief motivational intervention (MI)
Number of subjects: 167

Group type: COMPARATOR
Intervention: Time- and attention-matched control of meditation and relaxation training
Number of subjects: 167
Study: 25887086

Group type: EXPERIMENTAL
Intervention: PCV7
Number of subjects: 889

Group type: EXPERIMENTAL
Intervention: PCV10
Number of subjects: 889

Group type: EXPERIMENTAL
Intervention: PCV13
Number of subjects: 889

Group type: EXPERIMENTAL
Intervention: Mixed PCV10 + PCV13 schedule
Number of subjects: 889